Hsp90 inhibition and co‐incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T‐DM1

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review

(2019) Noam Pondé et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

(2019) Edith A. Perez et al.   CANCER

Antibody–drug conjugates for cancer

(2019) Cindy H Chau et al.   LANCET

HER2-targeted therapies — a role beyond breast cancer

(2019) Do-Youn Oh et al.   Nature Reviews Clinical Oncology

Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation

(2018) Markus Dietrich et al.   EXPERIMENTAL CELL RESEARCH

A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2

(2016) Monika Szymanska et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition

(2016) Srikumar M. Raja et al.   Oncotarget

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance

(2015) M. W. Pedersen et al.   MOLECULAR CANCER THERAPEUTICS

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer

(2014) Kathy D. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

(2013) G. D. L. Phillips et al.   CLINICAL CANCER RESEARCH

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

(2009) T. Ben-Kasus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA